Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Change in Accured Expenses (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Change in Accured Expenses for 2 consecutive years, with -$1.6 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 103.81% to -$1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.5 million for FY2025, 435.05% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$1.6 million at Neuphoria Therapeutics, down from $718261.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $2.3 million in Q2 2025, with the low at -$1.6 million in Q4 2025.